Generation of DC-based vaccine for therapy of B-CLL patients. Comparison of two methods for enriching monocytic precursors

References

• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245–52
   PubMed Web of Science ®Google Scholar
• Feuerstein B, Berger TG, Maczek C, et al. A method for the production of cryopreserved aliquots of antigen- preloaded, mature dendritic cells ready for clinical use. J Immunol Methods 2000; 245: 15–29
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Steinman RM, Sapp M, et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 1999; 104: 173–80
   PubMed Web of Science ®Google Scholar
• Stift A, Friedl J, Dubsky P, et al. Dendritic cell-based vaccination in solid cancer. J Clin Oncol 2003; 21: 135–42
   PubMed Web of Science ®Google Scholar
• Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004; 10: 475–80
   PubMed Web of Science ®Google Scholar
• Dallal RM, Lotze MT. The dendritic cell and human cancer vaccines. Curr Opin Immunol 2000; 12: 583–8
   PubMed Web of Science ®Google Scholar
• Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell 2001; 106: 271–4
   PubMed Web of Science ®Google Scholar
• Westermann J, Korner IJ, Kopp J, et al. Cryopreservation of mature monocyte-derived human dendritic cells for vaccination: influence on phenotype and functional properties. Cancer Immunol Immunother 2003; 52: 194–8
   PubMed Web of Science ®Google Scholar
• Kokhaei P, Rezvany MR, Virving L, et al. Dendritic cells loaded with apoptotic tumor cells induce a stronger T-cell response than dendritic cell-tumor hybrids in B-CLL. Leukemia 2003; 17: 894–9
   PubMed Web of Science ®Google Scholar
• Rouard H, Leon A, De Reys S, et al. A closed and single-use system for monocyte enrichment: potential for dendritic cell generation for clinical applications. Transfusion 2003; 43: 481–7
   PubMed Web of Science ®Google Scholar
• Vuillier F, Maloum K, Thomas EK, et al. Functional monocyte-derived dendritic cells can be generated in chronic lymphocytic leukemia. Br J Haematol 2001; 115: 831–44
   PubMed Web of Science ®Google Scholar
• Whiteside TL, Odoux C. Dendritic cell biology and cancer therapy. Cancer Immunol Immunother 2004; 53: 240–8
   PubMed Web of Science ®Google Scholar
• Kokhaei P, Choudhury A, Mahdian R, et al. Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL. Leukemia 2004; 18: 1810–15
   PubMed Web of Science ®Google Scholar
• Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219–34
   PubMed Web of Science ®Google Scholar
• Adamson L, Palmborg A, Svensson A, et al. Development of a technology platform for large scale clinical grade production of DC. Cytotherapy 2004; 6: 363–71
   PubMed Web of Science ®Google Scholar
• Boyum A. Separation of lymphocytes, lymphocyte subgroups and monocytes: a review. Lymphology 1977; 10: 71–6
   PubMed Web of Science ®Google Scholar
• Comby E, Andre I, Troussard X, et al. In vitro evaluation of B-CLL cell apoptotic responses to irradiation. Leuk Lymphoma 1999; 34: 159–66
   PubMed Web of Science ®Google Scholar
• Osterborg A, Yi Q, Henriksson L, et al. Idiotype immunization combined with granulocyte–macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood 1998; 91: 2459–66
   PubMed Web of Science ®Google Scholar
• Hirschowitz EA, Foody T, Kryscio R, et al. Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol 2004; 22: 2808–15
   PubMed Web of Science ®Google Scholar
• Hayashi T, Hideshima T, Akiyama M, et al. Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood 2003; 102: 1435–42
   PubMed Web of Science ®Google Scholar
• Gregoire M, Ligeza-Poisson C, Juge-Morineau N, Spisek R. Anti-cancer therapy using dendritic cells and apoptotic tumor cells: pre-clinical data in human mesothelioma and acute myeloid leukemia. Vaccine 2003; 21: 791–4
   PubMed Web of Science ®Google Scholar
• John J, Hutchinson J, Dalgleish A, Pandha H. Cryopreservation of immature monocyte-derived dendritic cells results in enhanced cell maturation but reduced endocytic activity and efficiency of adenoviral transduction. J Immunol Methods 2003; 272: 35–48
   PubMed Web of Science ®Google Scholar
• Wong EC, Maher VE, Hines K, et al. Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy. Cytotherapy 2001; 3: 19–29
   PubMed Web of Science ®Google Scholar
• Yannelli JR, Sturgill J, Foody T, Hirschowitz E. The large scale generation of dendritic cells for the immunization of patients with non-small cell lung cancer (NSCLC). Lung Cancer 2005; 47: 337–50
   PubMed Web of Science ®Google Scholar
• Ebner S, Ratzinger G, Krosbacher B, et al. Production of IL-12 by human monocyte-derived dendritic cells is optimal when the stimulus is given at the onset of maturation, and is further enhanced by IL-4. J Immunol 2001; 166: 633–41
   PubMed Web of Science ®Google Scholar
• Hokey DA, Larregina AT, Erdos G, et al. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity. Cancer Res 2005; 65: 10059–67
   PubMed Web of Science ®Google Scholar
• Vieira PL, de Jong EC, Wierenga EA, et al. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol 2000; 164: 4507–12
   PubMed Web of Science ®Google Scholar
• Mailliard RB, Wankowicz-Kalinska A, Cai Q, et al. Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 2004; 64: 5934–7
   PubMed Web of Science ®Google Scholar